<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81919">
  <stage>Registered</stage>
  <submitdate>19/03/2007</submitdate>
  <approvaldate>22/03/2007</approvaldate>
  <actrnumber>ACTRN12607000179437</actrnumber>
  <trial_identification>
    <studytitle>The effect of atorvastatin on lung function and morbidity as add-on therapy in asthmatic patients. A double-blind randomized cross-over trial.</studytitle>
    <scientifictitle>The effect of atorvastatin on lung function and morbidity as add-on therapy in normolipid asthmatic patients. A double-blind placebo controlled randomized cross-over trial.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Moderate to severe persistent asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>atorvastatin 10 mg per day oral for one month or placebo oral for one month,  each therapy separated with 2 weeks wash out period (cross-over)</interventions>
    <comparator>Placebo oral for one month,</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in Forced Expiratory Volume in one second (FEV1)</outcome>
      <timepoint>At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Forced Vital Capacity (FVC)</outcome>
      <timepoint>At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Peak Expiratory Flow (PEF)</outcome>
      <timepoint>At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in score of Jones Index of Morbidity</outcome>
      <timepoint>At baseline and after 4 weeks of each intervention (placebo or atorvastatin therapy).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Persistent moderate to severe asthma</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Dyslipidemia, adverse effect due to atorvastatin, other comorbid condition (heart failure, diabetes, MI, hypertension), receiving medication(s) interact with atorvastatin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation concealed by sealed opaque envelopes</concealment>
    <sequence>Simple randomisation by using a randomisation table from a statistic book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>the people receiving the treatment/s (subjects), the clinician administering the treatment/s, the researcher assessing the outcomes are blinded in the study</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/10/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>17</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shaheed Beheshti University of Medical Sciences, Iran</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Research Institute of Tuberculosis and Lung Disease</fundingname>
      <fundingaddress />
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Masih Daneshvari Hospital, Iran</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main goal of the study was to assess the effects of atorvastatin on asthma as an inflammatory disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Masih Daneshvari Hospital, NRITLD</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/10/2006</ethicapprovaldate>
      <hrec>500</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fanak Fahimi</name>
      <address>Masih Daneshvari Hospital
Shaheed Bahonar Ave
Darabad
Tehran 19569
P.O: 19575/154</address>
      <phone>+98 912 1940902</phone>
      <fax />
      <email>fahimi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fanak Fahimi</name>
      <address>Masih Daneshvari Hospital, Shaheed Bahonar Ave, Darabad, 
TEHRAN 19569, P.O: 19575/154</address>
      <phone>+98 912 1940902</phone>
      <fax>+98 21 22678090</fax>
      <email>fahimi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>